On 22 April 2026, Amneal Pharmaceuticals and Kashiv BioSciences jointly announced that Amneal will acquire 100% of Kashiv BioSciences. The deal (which is subject to approval by Amneal shareholders and regulatory authorities) is expected to close in the second half of 2026.
The acquisition includes a USD $375 million cash transaction and USD $375 million in equity payable at closing, with up to USD $350 million based on achievement of certain regulatory milestones, potential royalties based on commercial milestones, and funding of operations through closing.
The acquisition will combine Kashiv’s expertise in biosimilar development and manufacturing with Amneal’s scale and commercialisation capabilities. Kashiv and Amneal have previously entered strategic partnerships in relation to biosimilars in the US, including Fylnetra™ (biosimilar pegfilgrastim) in May 2022 and ADL018 (biosimilar omalizumab) in 2024.
In addition to Fylnetra™ and ADL018, Kashiv’s biosimilar pipeline includes Releuko™ (filgrastim-ayow) (FDA-approved March 2022), abatacept/KSHB002 (in clinical trials), certolizumab pegol and nivolumab (pre-clinical) and pembrolizumab (cell line and process development). Amneal’s biosimilar pipeline includes Alymsys® (bevacizumab) (FDA approved April 2022). Amneal also holds the exclusive US rights to mAbxience’s Boncresa™ and Oziltus™ (MB09), biosimilars to Amgen’s Prolia® and Xgeva® (denosumab) respectively (FDA approved December 2025).